Engrail Therapeutics, a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, announced the close of an oversubscribed $157 million Series B financing round.
In its most recent fundraising round, MakeO secured $16 million, or Rs 135 crore, with the help of 360 ONE (previously IIFL Wealth) and Ashish Kacholia's investment office.